+ T cell immunity is critical for protection from viral disease, such as that caused by the human immunodeficiency virus (HIV) or cytomegalovirus (CMV). It is therefore important to identify therapies that can boost antiviral immunity. The recent finding that thalidomide acts as a T cell costimulator suggested that this drug may boost antiviral CD8 + T cell responses. In this in vitro study, in a human autologous CD8 + T cell/dendritic cell (DC) coculture system, thalidomide and a potent thalidomide analogue were shown to enhance virus-specific CD8 + T cell cytokine production and cytotoxic activity. The drug-enhanced antiviral activity was noted in cells from both healthy donors and persons chronically coinfected with HIV and CMV. This stimulatory effect was directed at CD8 + T cells, and not DCs. These results suggest an application for thalidomide and the thalidomide analogue as a novel immune-adjuvant therapy in chronic viral infections.
virus, that are normally controlled by an intact immune response can cause disease when immunity is depressed, whether pharmacologically or by coincident HIV infection. The enhancement of virus-specific immunity is of clinical importance in these groups of patients and has therefore been attempted in various ways, including the administration of therapeutic vaccines [6, 7] , adoptive transfer of ex vivo-expanded virus-specific CD8 ϩ T cells [8, 9] , or immune-adjuvant therapy with recombinant interleukin (IL)-2 [10, 11] . A possible pharmacologic approach to immune enhancement is suggested by recent findings with the immune-modulatory drug thalidomide. Thalidomide's clinical anti-inflammatory activity was originally noted in erythema nodosum leprosum, a complication of leprosy [12] . The drug has since been shown to ameliorate the ulceration and inflammatory symptoms associated with Behçet's syndrome [13] . Similarly, thalidomide is also effective in reducing the aphthous ulceration associated with HIV disease [14] . Several activities of thalidomide have been described that may contribute to its clinical efficacy, including inhibition of the proinflammatory cytokine tumor necrosis factor-a (TNF-a) [15, 16] , inhibition of new blood vessel formation [17] , modulation of T cell function [18, 19] , and stimulation of natural killer cell responses [20] . However, the precise mecha-nism of action of the drug that accounts for its potency in various clinical situations remains unknown and may be multifactorial. Our recent work has focused on the effects of thalidomide on T cell responses. We demonstrated recently that thalidomide can act as a costimulator of T cell responses in vitro [18] . This costimulatory effect was manifested in a non-antigen-specific system by increased T cell proliferation and elevated cytokine production, exhibited by both CD8 ϩ and CD4
ϩ subsets. The subsequent findings that thalidomide treatment of patients with HIV infection [21, 22] , tuberculosis [23] , and scleroderma [24] is associated with immune activation, together with the observation that type 1 cytokine secretion is increased in healthy volunteers following a single dose of thalidomide [19] , suggests that the drug has the potential to stimulate T cell immunity in vivo. The latter activity may be desirable in diseases in which effector CD8 ϩ T cell responses are of critical importance, for example, in chronic infections with viruses such as HIV and CMV. The well-known teratogenic and neurotoxic potential of thalidomide imposes serious limitations on the use of this agent. For this reason, there has been intense interest in developing analogues of thalidomide with an improved therapeutic ratio. Two classes of thalidomide analogue have emerged, originally selected for their increased potency as inhibitors of TNFa production and their lack of teratogenicity in preliminary screening [25] . One of these classes comprises compounds that are inhibitors of phosphodiesterase IV [26] and that do not share the T cell-costimulating activity of the parent compound. Members of the other class are characterized by amino substitution of the phthalimide moiety of the parent molecule, are potent T cell costimulators, and, like thalidomide, lack phosphodiesterase IV inhibitory activity [27] . Herein we present the results of experiments done with thalidomide and one of the latter analogues (for molecular structure, see [27] , compound "8a"), called CC-5013. Of importance, the latter drug is presently in phase 1/2 human trials [28] .
To date, studies of the immune-modulatory activity of these agents have focused on their effect on non-antigen-specific immune responses. Here, with use of an in vitro dendritic cell (DC)/CD8 ϩ T cell coculture system, we tested whether thalidomide and CC-5013 have the potential to enhance virus-specific CD8 ϩ T cell effector function.
SUBJECTS, MATERIALS, AND METHODS
Study subjects. Healthy adults and asymptomatic chronically HIV-infected patients who were receiving HAART were eligible for enrollment in the study.
Cell preparation.
Peripheral blood mononuclear cells (PBMCs) were isolated from freshly drawn heparinized blood by ficoll density gradient separation.
Immature DCs were prepared from CD14 ϩ monocyte precursors by culture in recombinant human IL-4 (30 U/mL; Endogen) and recombinant human granulocyte-macrophage colony-stimulating factor (100 U/mL; Immunex), as described previously [29] . To achieve maturation of the DCs, In some experiments, virus-infected DCs were fixed with 0.05% glutaraldehyde, followed by quenching with 0.2 M L-lysine, as described [18] . Purified T cells or PBMCs were preincubated with 0.04% dimethyl sulfoxide (DMSO; diluent vehicle: negative control), thalidomide (4-40 mM), or CC-5013 (1 mM). These concentrations of the test compounds were found in previous studies to be optimal for costimulating T cell responses in nonantigen-specific systems [18, 25] . Cultures were set up in 48-well tissue culture plates at T cells or PBMCs per well in 1 6 2 ϫ 10 mL of RPMI 1640 medium supplemented with 10% human AB serum, penicillin, and streptomycin (R10). The concentration of DMSO was the same in all conditions (0.04%). After 1 h of preincubation, antigen-loaded DCs were added at a ratio of 1 DC per 100 T cells (or PBMCs).
DC/T cell cocultures were incubated for 6 days. During incubation, fresh DMSO, thalidomide, or analogue was added on alternate days. On day 6 of coculture, cells were harvested to assess T cell function.
In some experiments, cocultures were treated with a polyclonal rabbit anti-human IL-2 antibody, 10 mg/mL (Endogen), or control rabbit IgG, added on alternate days. 2 ϫ 10 V-bottomed tissue culture plate, and T cells were restimulated by the addition of autologous, virus-infected or peptide-pulsed DCs (DC to T cell ratio of 1:10-20). Brefeldin A (Sigma), 10 mg/mL, was added to block cytokine secretion, followed by incubation at 37ЊC for 5 h. Subsequently, cells were fixed with 4% paraformaldehyde and permeabilized by resuspension and washing in permeabilization buffer (PBS containing 0.1% saponin and 0.1% bovine serum albumin). Cells were stained in 50 mL of permeabilization buffer with combinations of 5 mL each of the following fluorescence-conjugated antibodies: anti-CD8, anti-interferon-g (IFN-g), anti-TNF-a, or anti-IL-2. All antibodies were obtained from Becton Dickinson. Subsequently, cells were washed twice in permeabilization buffer, resuspended in PBS, and transferred to plastic tubes for analysis with a FACScan flow cytometer (Becton Dickinson).
ELISpot assay. In some experiments, single-cell CD8 ϩ T cell IFN-g production was evaluated by the ELISpot assay, as described previously [30] . On day 6 of DC/CD8 coculture, 10 5 cells were harvested and placed in duplicate in a 96-well ELISpot plate (Millititer; Millipore) coated with anti-IFN-g monoclonal antibody (clone 1-DIK; MabTech), and restimulated with fresh DCs that had been infected with homologous vaccinia virus recombinants, at a DC to T cell ratio of 1:20. Cultures were incubated overnight. After incubation, cells were lysed and washed out, and spots of captured IFN-g were revealed with a secondary IFN-g monoclonal antibody (clone 7-B6-1; MabTech) conjugated to a peroxidase indicator system (Vector Laboratories). Resulting brown spots were counted with a dissecting microscope, each spot representing IFN-g production by a single cell.
Chromium-release assay. Standard 5-h 51 Cr-release assays were used to measure cytotoxic function. Effector cells were obtained from day 6 DC/CD8 cocultures and were resuspended in 1 mL of R10, as described above. Triplicate 100-mL aliquots of effectors were placed in 96-well U-bottomed tissue culture plates, and serial 3-fold dilutions were prepared. Results are therefore expressed per dilution of effectors, ranging from 1 (undiluted) to 27 (1/27 dilution). As target cells, 10 6 autologous DCs, infected in the same way as DCs used in the primary cocultures, were suspended in 100 mL of culture medium and incubated with 100 mCi of Na 51 CrO 4 for 1 h at 37ЊC. After 3 washes, radiolabeled DCs were resuspended in R10, and targets were added to each well of the effector cells. 3 5 ϫ 10 After 5 h of incubation at 37ЊC, 50 mL of supernatant medium/ well was harvested for measurement of g emission by means of a liquid scintillation counter (1450 "Trilux"; Wallac). For each effector population, parallel assays were set up with targets infected with the same virus used in the primary coculture and with control targets that were uninfected or infected with wild- type vaccinia virus. Spontaneous and total release were assessed for each target population after treatment with culture medium and 1% SDS, respectively. ) incorporation over 6 h by triplicate 50-mL aliquots of resuspended day 6 cocultures, after transfer to 96-well U-bottomed tissue culture plates. DNA was harvested onto fiber mats with an automatic cell harvester (Skatron), and b emission was measured with a liquid scintillation counter (1450 "Trilux"; Wallac).
Evaluation of DC function. DC cultures were treated with DMSO, thalidomide (0.4-40 mM), or CC-5013 (1 mM), at the time that CD40L-transfected fibroblasts were added. Supernatants were collected at 48 h for assay of total IL-12 by ELISA (Endogen), according to the manufacturer's instructions. At 72 h, DCs were evaluated phenotypically by flow cytometry to assess expression of CD83, CD80, CD86, HLA-DR, and CD14, or by their capacity to stimulate allogeneic T cell proliferation: serial triplicate dilutions of DCs were made in 96-well U-bottomed plates to which allogeneic purified T cells (10 5 /well) were added. Tritiated thymidine incorporation during the last 6 h of 120-h cultures was assayed.
RESULTS

Thalidomide and CC-5013 costimulate virus-specific CD8
+ T cell effector responses in DC/PBMC and DC/CD8 cocultures prepared from healthy donors. Monocytes prepared from the PBMCs of CMV-seropositive healthy adult volunteers were cultured in vitro to obtain mature DCs. The DCs were infected with the vaccinia virus constructs vacWT or vacpp65 and cocultured with autologous PBMCs at a DC to PBMC ratio of 1:100. On day 6, the cocultures were restimulated with DCs infected with the same vaccinia virus constructs for 5 h in the presence of brefeldin A. Subsequent IC/FACS analysis revealed CMV-spe- ϩ T cells from patient with chronic HIV disease. Experiment was set up as in figure 2C . B, 51 Chromium-release assay showing enhancement by thalidomide and CC-5013 of HIV Pol-specific target lysis. CMVspecific killing was observed after treatment of cocultures with CC-5013, but not with either dimethyl sulfoxide (DMSO control) or thalidomide. Assays were set up as in figure 2D . Black symbols represent lysis of antigen-pulsed targets by antigen-stimulated effectors; white symbols represent lysis of unpulsed control targets. CD8
ϩ T cells cocultured with unpulsed dendritic cells did not lyse either pulsed or unpulsed targets (not shown). Results are from 18 (intracellular cytokine staining) and 4 ( 51 Cr-release assays) independent experiments. To study CD8 ϩ T cell effector responses in more detail, we next evaluated the effect of thalidomide and CC-5013 on simultaneous IFN-g and TNF-a production, and cytotoxic activity of virus-specific CD8 ϩ T cells, by IC/FACS and 51 Crrelease assays, respectively. DC/CD8 cocultures were prepared as described above, and FACS analysis was done after restimulation of the cultures on day 6. Both influenza virus matrix peptide and CMV pp65 stimulated cytokine responses that were enhanced by thalidomide and further increased by CC-5013 ( figure 2A and 2C) . Of note, the majority of cytokine-positive cells coexpressed both IFN-g and TNF-a.
In parallel, effector cells were harvested on day 6 of the DC/ CD8 coculture, and their capacity to lyse antigen-pulsed 51 Crlabeled autologous DC targets was evaluated. Thalidomide and, to a greater extent, CC-5013 enhanced the lysis of influenza virus matrix peptide-pulsed DC targets (figure 2B), whereas only CC-5013 stimulated a detectable CMV-specific lytic re- sponse ( figure 2D ). The target cell lysis was antigen specific, because the same effectors did not lyse control targets that had not been pulsed with antigen (figure 2B) or that were infected with vacWT ( figure 2D) . Similarly, no lysis of target cells was observed in experiments in which non-antigen-pulsed or vacWT-infected DCs were used in the initial 6-day coculture, demonstrating that an antigenic stimulus is necessary for the drugs to exert their costimulatory effect and that priming or enhancement of vaccinia virus-specific lytic responses was not occurring to a measurable extent during the 6-day coculture. From these experiments, we conclude that, in healthy donors, thalidomide and CC-5013 can costimulate CD8 ϩ T cell effector functions against influenza virus and CMV, two viruses of clinical importance, in the absence of CD4 ϩ T cell help.
Thalidomide and CC-5013 promote HIV-and CMV-specific responses in CD8
+ T cells from chronically HIV-and CMVcoinfected persons. Next, we used the same autologous culture system to evaluate the potential of thalidomide and CC-5013 to enhance the virus-specific activities of CD8 ϩ T cells isolated from chronically HIV-infected patients who were undergoing treatment with HAART. DCs prepared from PBMCs obtained from these patients were infected with vacWT, vacGag, vacPol, vacEnv, vacNef, or vacCMV. The presence of baseline CD8 ϩ T cell responses to the individual HIV gene products by these patients had been determined previously in ELISpot assays [30] . In the present experiments, we observed that thalidomide and CC-5013 enhanced HIV-and CMV-specific IFN-g and TNF-a expression by CD8 ϩ T cells, as well as virus-specific lytic activity (figure 3). Table 1 shows the IFN-g data from 6
independent experiments done with cells isolated from 6 HIVinfected patients. In general, the immune-modulatory compounds enhanced HIV-and CMV-specific responses (P ! .01 and , respectively, by Freidman's nonparametric analysis P ! .05 of variance by ranks). Thus, thalidomide and CC-5013 can stimulate HIV-and CMV-specific immunity in CD8 ϩ T cells from chronically HIV-infected patients currently undergoing treatment with HAART.
Thalidomide enhances virus-specific responses by stimulating autocrine IL-2-driven expansion of effector CD8 + T cells. In direct ex vivo assays in which DC/CD8 cocultures were immediately treated with brefeldin A and IC/FACS analysis was done after 5 h, thalidomide had little or no enhancing effect on virus-specific IFN-g responses (data not shown). In contrast, after 5-7 days of in vitro expansion of CD8 ϩ cells by coculture with DCs, the enhancing effect of thalidomide and CC-5013 was apparent, suggesting that the drugs were enhancing clonal expansion of antigen-specific memory-effector CD8 ϩ T cells. In support of this, [ 3 H]-thymidine incorporation was increased when DC/CD8 cocultures were set up in the presence of thalidomide or CC-5013 ( figure 4A ). Parallel evaluation of intracellular IL-2 expression in restimulated day 6 cocultures revealed consistent increases in numbers of IL-2-positive CD8 ϩ T cells ( figure 4B ). When cultures were treated with a neutralizing antibody against IL-2, the thalidomide-induced expansion of antigen-specific CD8 ϩ T cells was largely reversed ( figure 4C ). Control experiments confirmed that the IL-2-neutralizing antibody did not cross-react with IFN-g (not shown). These results strongly suggest that, in our experimen- tal system, the enhancement of virus-specific CD8 ϩ T cell responses by thalidomide is a consequence of pharmacologic costimulation of CD8 ϩ T cell IL-2 production.
Thalidomide and CC-5013 exert a direct costimulatory effect on CD8
+ T cells and do not enhance costimulation by DCs. In the experiments described thus far, both DCs and T cells were exposed to the experimental immune-modulating compounds. It was therefore possible that the augmented T cell responses observed were due to pharmacologic enhancement of DC function and/or direct effects on T cells. To address this, we performed experiments to evaluate the effect of thalidomide on key DC functions that could, in turn, increase T cell responsiveness: that is, IL-12 production [31] , expression of surface molecules involved in T cell activation, and the capacity of DCs to prime an allospecific T cell response.
Immature DCs, obtained from healthy HIV-uninfected persons, were incubated with thalidomide or CC-5013 during CD40L-induced DC maturation. CD40L is a potent stimulus of IL-12 production. This cytokine is maximally produced as the DCs mature to become highly efficient antigen-presenting cells [32] . IL-12 was assayed in culture supernatants at 48 h. At this time, DCs were harvested and assayed by FACS analysis for surface molecule expression or were combined with HLAmismatched purified T cells to assess their capacity to prime an allospecific lymphoproliferative response. We observed that neither thalidomide nor CC-5013 enhanced IL-12 production by DCs, but rather both drugs exerted a modest inhibitory effect on the secretion of this cytokine by these cells ( figure  5A ). On analysis of surface marker expression by FACS, we observed no effect of the drugs on the expression of the DC maturation marker CD83, the costimulatory molecules CD80 or CD86, or the antigen-presenting molecule HLA-DR ( figure  5B ). This lack of effect was confirmed functionally, because the drugs had no effect on the allostimulatory capacity of DCs ( figure 5C ). These experiments suggested that thalidomide and CC-5013 were unlikely to exert their T cell-costimulatory effect via direct augmentation of DC function.
Finally, we performed experiments in which mature DCs that had been infected with vaccinia virus constructs were fixed with glutaraldehyde before coculture with autologous CD8 ϩ T cells, so that any biologic effect of the experimental agents in this antigen-specific system would have to be directed at the T cell. After 6 days, the CD8 ϩ T cells were restimulated with infected (unfixed) DCs in ELISpot plates. The thalidomide-induced boosting of T cell responses was evident regardless of whether the DCs used for the initial stimulation had been fixed ( figure  6 ). Indeed, the effect of thalidomide relative to DMSO control-treated cultures was even more striking after DC fixation, because fixation reduced the T cell response to antigen in the absence of thalidomide (figure 6). We conclude from these experiments that thalidomide and CC-5013 exert their immune-stimulatory effect directly on CD8 ϩ T cells, that they can do so in the absence of CD4 ϩ T cells, and that this effect is not by increasing the efficiency of antigen presentation.
DISCUSSION
Herein, we show that, in vitro, thalidomide and a selected thalidomide analogue enhance antigen-specific CD8 ϩ T cell responses against HIV, CMV, and influenza virus-all viruses of clinical importance. Our data indicate that the stimulatory effect of the drugs is directed at the T cell and is not accounted for by direct augmentation of antigen-presenting cell function. These studies support the hypothesis that thalidomide has an immune-adjuvant effect and, thus, may be of clinical utility for diseases in which enhancement of antigen-specific CD8 ϩ T cell immunity is desirable, such as in chronic viral infections or cancer.
In previous clinical studies, we have shown that thalidomide treatment of patients with HIV infection [21, 22] , tuberculosis and HIV coinfection [23] , scleroderma [24] , and sarcoidosis [33] is associated with immune activation. One feature of this is consistently increased IL-12 production. This has also been demonstrated recently in healthy volunteers treated with thalidomide [19] . However, IL-12 is produced by antigen-pre-senting cells, not T cells, whereas the data presented here suggest that the immune-stimulatory effects of thalidomide are directed at the T cell rather than the antigen-presenting cell. To explain this apparent contradiction, the physiologic regulation of IL-12 production must be considered. IL-12 production by antigen-presenting cells (DCs and monocytes) is stimulated by activated T cells that express CD40L (T cell-dependent pathway-mimicked in the present work by CD40L-expressing fibroblasts) or by pathogen-associated molecules, such as lipopolysaccharide (T cell-independent pathway). In the present report, in contrast to the consistent and direct costimulatory effect of thalidomide and CC-5013 on CD8
ϩ T cell function, we show that the direct effect of these drugs on CD40 ligand-induced IL-12 production by DCs was modestly inhibitory. This is consistent with the findings of Moller et al. [34] , which demonstrate that thalidomide directly inhibits T cell-independent monocyte production of IL-12 in a dose-dependent manner. To reconcile the different effects of thalidomide on IL-12 production, we suggest that, in the clinical settings cited above, costimulation of T cells by thalidomide results in the up-regulation of T cell signals (i.e., CD40 ligand and IFN-g) for antigen-presenting cells to produce IL-12 [22, 25] , outweighing the direct inhibitory effects of the drug on the latter cells. However, it is possible that, in some clinical situations, the effect of the drug on IL-12 levels in vivo will be inhibitory if the predominant stimulus for IL-12 production is microbial (i.e., T cell independent). Indeed, in vitro experiments have revealed this dichotomy: when peripheral blood mononuclear cells are stimulated by T cell receptor activation, thalidomide enhances IL-12 production, but, when PBMCs are stimulated by lipopolysaccharide, thalidomide inhibits the production of this cytokine [25] . Analogues of thalidomide that possess enhanced potency as T cell costimulators have been described recently [25] . Here we show that CC-5013, an analogue compound that is currently in phase 1/2 clinical trials [28] , also displayed increased potency, relative to thalidomide, in enhancing antigen-specific CD8 ϩ T cell responses. Further support for the potential importance of an immune-enhancing or adjuvant effect of this class of compounds was provided in a recent publication by Dredge et al. [35] , which showed that another T cell-costimulating thalidomide analogue, CC-4047, potently enhanced protective antitumor immunity when administered to mice during the priming phase of tumor cell immunization. The identification of the molecular target(s) of thalidomide and its analogues that mediate this immune-adjuvant activity will be of crucial importance in refining analogue development and, more generally, in identifying potentially new cellular targets for immune-modulatory therapy. A key unanswered question is how, or whether, the putative immune-adjuvant effects of thalidomide are related to the clinical effects observed during therapy with this drug. "Paradoxical" exacerbations of some diseases have been reported following thalidomide treatment, in graft-versus-host disease [36] , toxic epidermal necrolysis [37] , and tuberculosis meningitis [38] , which are readily explained by pharmacologic enhancement of T cell activity. However, in those conditions in which there is controlled evidence of clinical benefit-erythema nodosum leprosum [12] and HIV-or Behçet's syndrome-associated mucosal ulceration [13, 14] -the apparent effect of the drug is anti-inflammatory. The TNF-a-inhibitory activity of thalidomide is an appealing and widely accepted explanation for the latter responses. However, it is possible that the T cell-directed immune-adjuvant effect of thalidomide may promote active immune regulation. This may occur via stimulation of regulatory T cell subsets [39] or by the induction of IL-2-dependent control of memory T cell populations [40] , resulting in resolution of inflammation. Recent clinical studies by our group suggest that thalidomide promotes an active healing process when used in the treatment of cutaneous sarcoidosis, in which therapy is associated with maturation, followed by involution of sarcoid granulomata [33] . The hypothesis that thalidomide stimulates host immune regulation will be tested in further, detailed clinical-immunologic studies. This area of investigation may lead to the development of alternative approaches to treating inflammatory diseases, approaches that harness the host's active immune-regulatory potential.
In summary, we show here that thalidomide and CC-5013, a thalidomide analogue currently in clinical trials, are costimulators of virus-specific CD8 ϩ T cell effector functions. These data contribute to a growing body of evidence that thalidomide has immune-potentiating effects. Further studies will elucidate the relevance of this activity of the drug to the known clinical benefits of thalidomide and will permit prospective testing of the hypothesis that useful stimulation of antiviral immunity can be achieved with these agents in the clinic.
